Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01855828|
Recruitment Status : Completed
First Posted : May 17, 2013
Results First Posted : March 31, 2020
Last Update Posted : March 31, 2020
|Condition or disease||Intervention/treatment||Phase|
|Her2-Positive Breast Cancer||Drug: Pertuzumab Drug: Trastuzumab Drug: Paclitaxel Drug: 5-fluorouracil Drug: Epirubicin Drug: Cyclophosphamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||August 2018|
|Actual Study Completion Date :||August 2018|
Experimental: Chemo plus Pertuzumab,Trastuzumab
During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
Other Name: Perjeta
For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).
For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).
Other Name: Herceptin
Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
Other Name: Taxol
Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Other Name: 5-FU
Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
Other Name: Ellence
Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Other Name: Cytoxan
- Proportion of Participants With a Pathologic Complete Response Rate [ Time Frame: 20 weeks ]To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer. This study will assess pCR rates separately in ER+ and ER- cancers. Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen. Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen.
- Cardiac Safety [ Time Frame: Up to 1 year post surgery ]To assess the safety of the regimen, cardiac safety was measured by rates of clinically symptomatic congestive heart failure, asymptomatic decrease in LVEF >10%, and decrease of LVEF below normal level. This was assessed up to 1 year following surgery.
- Count of Patients With Clinical Response [ Time Frame: Up to 28 weeks ]To assess clinical response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, the number of patients are presented with a clinical response.
- Residual Cancer Burden Score [ Time Frame: Up to 28 weeks ]To assess cancer burben, the Residual Cancer Burden (RCB) score was used. This score has a range of 0 - III, where III (3) is the worst level of burden.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01855828
|United States, Connecticut|
|Yale University Smilow Cancer Hospital|
|New Haven, Connecticut, United States, 06520|
|Principal Investigator:||Lajos Pusztai, MD||Yale University|